Xenetic Biosciences, a biopharmaceutical company focused on advancing immune-oncology technologies addressing hard-to-treat cancers, has entered into a manufacturing agreement with Catalent Pharma Solutions, which will include cGMP manufacturing for the company’s recombinant protein, Human DNase I. “We are pleased to be working with a preeminent contract development and manufacturing organization (CDMO) such as Catalent, and to have the opportunity to leverage their broad expertis...